Introduction
The continuing heavy burden of congestive heart failure (CHF) is due, at least in part, to limitations in our diagnostic capabilities. Regardless of the efficacy of available interventions, they cannot improve clinical outcomes unless patients have been correctly identified as appropriate recipients. Diagnosis is complicated by the non-specific nature of the individual signs and clinical symptoms of CHF, which include breathlessness, fatigue, and peripheral oedema. These only suggest CHF as the most likely diagnosis when co-existing, and even then might indicate other conditions, such as respiratory insufficiency. This article reviews some of the key issues likely to arise during the assessment of patients with suspected CHF, highlighting potential pitfalls and suggesting ways in which diagnosis might be improved.
Current evidence of misdiagnosis in CHF
The current status of CHF diagnosis may be described by a 'rule of halves' (Figure 1 ). Of the patients receiving treatment for CHF, only about one-half actually show evidence of cardiac dyfunction and, of those with demonstrable dysfunction, perhaps fewer than one-half have left ventricular systolic impairment (the most easily recognised form of CHF). Fewer than one-half of these individuals receive appropriate therapy, while patients with diastolic heart failure may not be identified at all and so stand no chance of receiving appropriate management.The problematic nature of diagnosis is a matter of concern as CHF prevalence continues to rise, particularly because of the ageing population and increased survival rates after myocardial infarction. In addition, because CHF is a clinical syndrome, rather than a single pathological condition, the choice of appropriate therapy depends entirely on the precise nature of cardiac impairment and its correct identification.
A review of current diagnostic processes has identified five objectives ( Table 1) , each of which is important in tailoring the best treatment to an individual patient.
The definition of CHF
The lack of a universally accepted definition of CHF represents the first problem in diagnosis. Although CHF is commonly defined as the state in which the heart is unable to pump blood at a rate
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Thomas F Lüscher that satisfies metabolic requirements (or to do so only as a result of elevated filling pressure), 2 clinicians ideally require a more practical working description. That provided by the Task Force on Heart Failure of the European Society of Cardiology (ESC) 3 is widely used. Noting that 'a simple objective definition of heart failure is currently impossible, as there is no cut-off value of cardiac or ventricular dysfunction or change in flow that can be used reliably to identify patients with heart failure', the ESC definition requires subjective symptoms (breathlessness, fatigue, ankle swelling) supported by objective evidence of cardiac dysfunction and, preferably, by an appropriate response to treatment ( Table 2) .
Objective evidence of CHF
Although the ESC definition requires 'objective evidence of cardiac dysfunction', commonly used methods rely, to some extent, on subjective judgement. There may, for instance, be disagreement between observers on the degree of pulmonary congestion shown by a radiograph. 4 A normal chest radiograph does not necessarily imply normal cardiac function, while left ventricular dilatation is absent in many patients with left ventricular impairment.
A 12-lead electrocardiograph (ECG) remains an essential facet of diagnosis. A normal ECG is unusual in secondary CHF, but abnormal ECG findings (infarct signs, bundle branch block, hypertrophy) are not specific and do not, in themselves, indicate CHF as the cause of signs or symptoms that are apparently of this aetiology. Similarly, the combination of a normal ECG with a normal chest radiograph does not exclude CHF as a possible diagnosis. 1 Echocardiography has the appeal of providing both structural and functional information in a non-invasive way, and many cardiologists would regard the management of patients with suspected CHF to be incomplete without the support of this technique ( Table 3 ). The definition of significant left ventricular dysfunction by echocardiography is, however, arbitrary. Varying degrees of left ventricular ejection fraction (LVEF) have, for instance, been used to define ventricular systolic dysfunction. Typically, the lower limit of the normal range for LVEF is considered to be 40%, although a limit of 35% has also been used. In addition, because LVEF reflects only the proportion of the ventricular volume expelled during systole, marked ventricular diastolic dysfunction may be present in the absence of an abnormal LVEF.
Biochemical markers can also complement physiological measurements and are important additional diagnostic tools. Concentrations of natriuretic peptides, for example, are raised in CHF and, to a lesser extent, in asymptomatic cardiac impairment. Their measurement may therefore prove a useful means of improving the accuracy of CHF diagnosis. BNP (brain-type natriuretic peptide), secreted mainly by the ventricles, is strongly predictive of left ventricular dysfunction following myocardial infarction, while ANP (atrial natriuretic peptide) and BNP may both be useful in the detection of asymptomatic cardiac impairment, as discussed below.
Assays for such natriuretic peptides have the further advantage of being inexpensive and easy to perform. NT-ANP (N-terminal ANP) and BNP remain stable for many hours, so blood sampling in primary care is a practical proposition. The levels of these peptides are, however, also increased in renal impairment and serum creatinine must therefore also be assessed to eliminate any contribution of renal dysfunction to an abnormal result.
The usefulness of these assays has been investigated in the primary care setting in the UK. 5 In this trial, general practitioners serving a population of 151,000 referred all suspected cases of new CHF to a rapid-access clinic, where the patients were assessed by a cardiologist utilising ECG, chest radiography and transthoracic Table 3 Value of echocardiography in the diagnosis of heart failure.
Prognostic information: Ejection fraction

Form of heart failure:
Systolic vs. diastolic dysfunction
Causes:
Signs of coronary artery disease (aneurysm, regional wall motion abnormalities) Valvular heart disease Rare causes (amyloidosis, etc.)
Severity:
Ejection fraction Pulmonary pressure (systolic) echocardiography, together with assays for ANP, BNP and NT-ANP. In addition, the diagnosis was confirmed, using ESC guidelines, by a panel of three cardiologists unaware of the levels of the natriuretic peptides (Table 4 ). The study confirmed that levels of the peptides were much higher in patients with CHF than in those with other conditions. The researchers concluded that, although natriuretic peptide assays would not be a substitute for clinical judgement, they may help the general practitioner to decide whether the patient needs referral for further cardiology assessment. Newer, potentially interesting biochemical markers include the endothelins. Indeed, plasma levels of GF-1 correlate with haemodynamics and symptoms in patients with CHF.
Recognition of diastolic heart failure
Many patients, particularly the elderly, with signs and symptoms of CHF, do not have marked abnormalities in left ventricular systolic function, but show disordered diastolic filling of the left ventricle. 6 The prevalence of diastolic dysfunction remains uncertain, but estimates from the USA suggest that this aetiology may account for 42% of all cases of CHF. 7 Prevalence has, however, been lower in other US 8 and British 9 studies. An abnormally small heart shadow on the chest radiograph, combined with signs of congestion, is highly suggestive of CHF, although echocardiography is the best confirmatory test. The European Study Group on Diastolic Heart Failure has proposed a set of diagnostic criteria using well-defined indices of left ventricular function obtained during cardiac catheterization or non-invasive imaging. 10 A diagnosis of diastolic heart failure must be supported by signs or symptoms of CHF, normal or only mildly abnormal left ventricular systolic function, and evidence of abnormal left ventricular relaxation, filling, diastolic distensibility or diastolic stiffness.
The differential diagnosis of diastolic, as opposed to systolic, CHF is vitally important, because treatments suitable for systolic CHF may be unsuitable for its diastolic counterpart. An increased left atrial pressure, for example, may be essential to maintain left ventricular filling pressure during diastolic heart failure, so that a pressure reduction induced by the inappropriate use of an ACE inhibitor may reduce ventricular filling to such an extent that the patient deteriorates.
How far, ethically, should we investigate aetiology?
There are three reasons for investigating CHF aetiology: (i) to identify reversible exacerbating factors such as alcohol abuse, hyperthyroidism, and atrial fibrillation (it is, however, unusual in practice to find a correctable cause), (ii) to rationalise therapeutic decisions, and (iii) to provide prognostic information. For instance, in a study of 3787 patients with left ventricular dysfunction, those with ischaemia (determined by coronary angiography) had a 59% five-year survival, whereas those with non-ischaemic cardiomyopathy had a better prognosis (69% five-year survival). 11 A recent study has also shown that patients with the rare peripartum cardiomyopathy have a good prognosis, whereas those with cardiomyopathy due to HIV, amyloidosis or doxorubicin have a worse prognosis than those with idiopathic nonischaemic cardiomyopathy. 12 The central question, which must be carefully debated, is whether it is reasonable to investigate solely for prognostic purposes in cases where there is little or no possibility of cause-specific therapy. 13 Clinical assessment may, for instance, be misleading -in the study of 3787 patients mentioned above, one third of those with nonischaemic cardiomyopathy had typical angina, and could easily have been misclassified as having ischaemic heart failure. Similarly, endomyocardial biopsy may determine the cause of non-ischaemic heart failure, but may be inconclusive and carries a risk of cardiac perforation and death.
Are some misdiagnoses inevitable in primary care?
A classic study of patients with CHF due to ischaemic heart disease investigated by angiography has shown the limitations of signs and symptoms alone as a means of diagnosis (Table 5 ). 14 Symptoms are sensitive, but may not be specific. Most of the classic physical signs attributed to CHF are surprisingly insensitive but relatively specific -for example, rales, peripheral oedema, tachycardia and neck vein distension were found infrequently in patients with CHF but, when present, were relatively specific indicators of the condition. Application of the ESC diagnostic guidelines should reduce or even eliminate misdiagnoses. However, the necessary investigations to provide 'objective evidence of cardiac failure' may not be readily available to the primary care physician. This explains why fewer than half of all patients with a primary care diagnosis of CHF have evidence of CHF on further assessment. 15
Early diagnosis: should patients be screened and, if so, how?
CHF represents the end stage of a progressive deterioration in left ventricular function that can remain clinically silent for years before the development of overt symptoms. 16 Between 1% and 2% of adults in the community at large may have asymptomatic left-ventricular dysfunction (i.e., LVEF < 35%). 17 It is important to detect such individuals, because treatment with ACE inhibitors can markedly decrease both morbidity and mortality. Screening of high-risk groups is, therefore, probably justifiable to aid the selection of patients for treatment of proven benefit. 5 Such high-risk patients include those with angina, a history of myocardial infarction, hypertension or diabetes. In a study of 2000 men and women randomly sampled from one geographical area in the UK, for example, the combination of hypertension and ischaemic heart disease was a powerful predictor of left-ventricular systolic dysfunction. 18 Hypertension alone was not, however, more common in those with impaired ventricular function. In contrast, the US Framingham Study found hypertension to be the predominant risk factor for CHF. 19 Other screening investigations might include assays of NT-ANP and BNP, both of which are increased in the early stages of asymptomatic left ventricular dysfunction. 20 BNP appears the more accurate indicator of the two, a study having shown that a BNP concentration < 18 pg/mL indicates a low likelihood of left-ventricular systolic dysfunction. 21 Although population screening for left ventricular dysfunction is unlikely to be cost-effective, targeted screening of those at high risk could permit more economical use of further investigations, such as echocardiography.
A recent Danish study has followed this approach by identifying patients with existing or past signs or symptoms of heart disease, the aim being to determine predictors of left ventricular systolic dysfunction in order to rationalise selection for echocardiography. 22 Of 2158 patients over the age of 40 years, screened by questionnaires and record reviews, 126 eventually underwent further tests, including echocardiography. Multivariate analysis identified three variables that predicted systolic dysfunction -an abnormal ECG result, a resting heart rate numerically greater than the diastolic blood pressure, and a raised NT-ANP level. Interestingly, ECG was the most useful test in this primary care population, the risk of systolic dysfunction being very low in patients with a normal ECG trace.
Disability assessment
Studies have shown that patients with CHF report a very poor quality of life, which depends on both physical and psychological health. 23 Disability assessments should therefore include not only symptoms and exercise capacity (NYHA classification), but also mental state, as anxiety and depression are probably commonly concealed or ignored.
Organisation of diagnostic services
The key to the diagnosis of ventricular dysfunction and CHF is therefore their recognition in primary care and the initiation of appropriate confirmatory investigations. This raises questions regarding the organisation of diagnostic services, studies having shown that patients managed by cardiologists are more likely to undergo appropriate investigations, and to receive an ACE inhibitor at adequate doses. 24 In the absence of sufficient resources to allow specialist management of all CHF patients, would direct access by primary care physicians to non-invasive investigations, such as echocardiography, be sufficient, 25 or should measurement of natriuretic peptides be more widely available? Studies to address these and similar questions are now being initiated.
Conclusion
Key to the successful management of CHF is the correct identification of patients and the accurate assessment of the aetiology of the condition.This involves the effective use of primary care investigations to screen patients, ensuring that the limited resources available for further diagnosis are targeted towards those individuals who are most likely to require such services. This co-ordinated approach involving primary and secondary care optimises available resources to maximise diagnostic accuracy, thereby allowing appropriate therapies to be employed at an early stage to improve outcomes and the quality of the lives of those affected.
